ATE363471T1 - Durch einen morpholinrest substituierte therapeutische verbindungen - Google Patents
Durch einen morpholinrest substituierte therapeutische verbindungenInfo
- Publication number
- ATE363471T1 ATE363471T1 AT01902568T AT01902568T ATE363471T1 AT E363471 T1 ATE363471 T1 AT E363471T1 AT 01902568 T AT01902568 T AT 01902568T AT 01902568 T AT01902568 T AT 01902568T AT E363471 T1 ATE363471 T1 AT E363471T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase
- diseases
- compounds
- conditions
- platelet
- Prior art date
Links
- 150000001875 compounds Chemical group 0.000 title abstract 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 3
- 150000003906 phosphoinositides Chemical class 0.000 abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010011086 Coronary artery occlusion Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- -1 Morpholino-substituted pyridopyrimidine Chemical class 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17735100P | 2000-01-24 | 2000-01-24 | |
| US22582600P | 2000-08-17 | 2000-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE363471T1 true ATE363471T1 (de) | 2007-06-15 |
Family
ID=26873182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01902568T ATE363471T1 (de) | 2000-01-24 | 2001-01-24 | Durch einen morpholinrest substituierte therapeutische verbindungen |
| AT07009194T ATE551325T1 (de) | 2000-01-24 | 2001-01-24 | Therapeutische morpholino-substituierte verbindungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07009194T ATE551325T1 (de) | 2000-01-24 | 2001-01-24 | Therapeutische morpholino-substituierte verbindungen |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US6977255B2 (enExample) |
| EP (2) | EP1857443B1 (enExample) |
| JP (1) | JP4820518B2 (enExample) |
| CN (3) | CN1263743C (enExample) |
| AT (2) | ATE363471T1 (enExample) |
| AU (2) | AU2001230426C1 (enExample) |
| CA (1) | CA2398163C (enExample) |
| CY (1) | CY1108023T1 (enExample) |
| DE (1) | DE60128655T2 (enExample) |
| DK (1) | DK1257537T3 (enExample) |
| ES (1) | ES2286093T3 (enExample) |
| NZ (1) | NZ520300A (enExample) |
| PT (1) | PT1257537E (enExample) |
| WO (1) | WO2001053266A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| DK2223922T3 (en) | 2000-04-25 | 2016-06-06 | Icos Corp | Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA |
| GB0119863D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB0119865D0 (en) * | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| GB2405870B (en) * | 2001-08-14 | 2005-07-06 | Cancer Rec Tech Ltd | DNA-PK inhibitors |
| TW589181B (en) * | 2001-09-05 | 2004-06-01 | Eisai Co Ltd | Lymphocytic activation inhibitor and remedial agent for autoimmune disease |
| US7049313B2 (en) | 2002-02-25 | 2006-05-23 | Kudos Pharmaceuticals Ltd. | ATM inhibitors |
| EP2311818B1 (en) * | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| AR038703A1 (es) | 2002-02-28 | 2005-01-26 | Novartis Ag | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 |
| CN100430389C (zh) * | 2002-08-16 | 2008-11-05 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
| JP4646626B2 (ja) * | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド３−キナーゼβの阻害 |
| KR101050700B1 (ko) | 2002-08-26 | 2011-07-20 | 다케다 야쿠힌 고교 가부시키가이샤 | 칼슘 수용체 조절 화합물 및 이의 용도 |
| JP2006510661A (ja) | 2002-12-06 | 2006-03-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体 |
| GB0305152D0 (en) | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| WO2004092154A1 (en) * | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| JP2006523237A (ja) * | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ， インコーポレイテッド | Ｐｉ−３キナーゼインヒビタープロドラッグ |
| MXPA05013210A (es) * | 2003-06-05 | 2006-03-09 | Warner Lambert Co | Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos. |
| US20040259926A1 (en) * | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
| JP2006526608A (ja) * | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド |
| BRPI0413467A (pt) | 2003-08-13 | 2006-10-17 | Kudos Pharm Ltd | aminopironas e seu uso como inibidoras da atm |
| BRPI0414171A (pt) * | 2003-09-04 | 2006-10-31 | Warner Lambert Co | benzo[b]tiofenos halossubstituìdos com atividade inibidora de pi3k como agentes terapêuticos |
| ATE365732T1 (de) * | 2003-10-31 | 2007-07-15 | Warner Lambert Co | Pyrimidine als inhibitoren von phosphoinositid-3- kinasen (pi3k) |
| WO2005095406A1 (en) * | 2004-01-26 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| EP1761540B1 (en) | 2004-05-13 | 2016-09-28 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| CN1300163C (zh) * | 2004-06-23 | 2007-02-14 | 南京大学 | 3－羟基色原酮糖苷及其制法和用途 |
| US7402607B2 (en) | 2004-09-20 | 2008-07-22 | Kudos Pharmaceuticals Limited | DNA-PK inhibitors |
| JP2008529995A (ja) | 2005-02-09 | 2008-08-07 | クドス ファーマシューティカルズ リミテッド | Ａｔｍ阻害剤 |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| WO2007127366A2 (en) | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
| WO2007147217A1 (en) * | 2006-06-22 | 2007-12-27 | Prana Biotechnology Limited | Method of treatment of glioma brain tumour |
| US8106071B2 (en) * | 2007-02-21 | 2012-01-31 | Biobud Co., Ltd. | Compositions for treating hyperproliferative vascular disorders and cancers |
| JP5672699B2 (ja) | 2007-04-11 | 2015-02-18 | 味の素株式会社 | 血糖降下作用化合物のスクリーニング法 |
| EP2154965A4 (en) * | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| US20100130597A1 (en) * | 2007-07-06 | 2010-05-27 | The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service | Dna-pkcs modulates energy regulation and brain function |
| RU2010133715A (ru) * | 2008-01-25 | 2012-02-27 | Астразенека Аб (Se) | ЭНАНТИОМЕРНО ЧИСТАЯ (-)2-[1-(7-МЕТИЛ-2-(МОРФОЛИН-4-ИЛ)-4-ОКСО-4Н-ПИРИДО[1,2-a]ПИРИМИДИН-9-ИЛ)БЕНЗОЙНАЯ КИСЛОТА, ЕЕ ПРИМЕНЕНИЕ В ФАРМАКОТЕРАПИИ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ |
| JP2011518174A (ja) * | 2008-04-18 | 2011-06-23 | シェノゲン ファーマ グループ リミテッド | エストロゲン受容体に関連する疾患を処置するための化合物及び方法 |
| AU2009295948B2 (en) | 2008-09-29 | 2013-12-05 | GlaxoSmithKline, LLC | Quinazolinone, quinolone and related analogs as sirtuin modulators |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| KR20160091440A (ko) | 2008-11-13 | 2016-08-02 | 길리아드 칼리스토가 엘엘씨 | 혈액 종양에 대한 요법 |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| NZ597579A (en) | 2009-07-02 | 2013-06-28 | Sanofi Sa | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors |
| ES2627428T3 (es) | 2009-07-02 | 2017-07-28 | Sanofi | Nuevos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona, su preparación y su utilización farmacéutica |
| WO2011001115A1 (fr) | 2009-07-02 | 2011-01-06 | Sanofi-Aventis | Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb ) |
| MX2012000103A (es) | 2009-07-02 | 2012-05-22 | Sanofi Sa | Nuevos derivados de 1,2,3,4-tetrahidro-pirimido (1,2-a) pirimidin-6-ona, su preparacion y su uso farmaceutica. |
| AU2010276160A1 (en) | 2009-07-21 | 2012-02-09 | Gilead Calistoga Llc | Treatment of liver disorders with PI3K inhibitors |
| US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| IT1403156B1 (it) * | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi. |
| FR2969613B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique |
| FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| US8815853B2 (en) | 2010-12-23 | 2014-08-26 | Sanofi | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof |
| LT2658844T (lt) | 2010-12-28 | 2017-02-10 | Sanofi | Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių |
| JP6000986B2 (ja) * | 2012-01-26 | 2016-10-05 | 第一三共株式会社 | 骨形成促進作用を有するクロモン誘導体 |
| ES2697174T3 (es) * | 2012-02-10 | 2019-01-22 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| KR102099997B1 (ko) | 2012-03-01 | 2020-04-13 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| EA025407B1 (ru) | 2012-03-05 | 2016-12-30 | Джилид Калистога Ллс | Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она |
| US9914722B2 (en) | 2012-03-23 | 2018-03-13 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| ITMI20120514A1 (it) * | 2012-03-29 | 2013-09-30 | Cnr Consiglio Naz Delle Ric Erche | Agente terapeutico per il trattamento dei vasi sanguigni |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| NZ720867A (en) | 2013-12-20 | 2018-01-26 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
| WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
| JP6455995B2 (ja) | 2014-06-13 | 2019-01-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
| JP6749343B2 (ja) * | 2015-05-20 | 2020-09-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための化合物 |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| KR20220100719A (ko) | 2015-12-10 | 2022-07-15 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| ES2818531T3 (es) | 2015-12-17 | 2021-04-13 | Biokine Therapeutics Ltd | Moléculas pequeñas para inhibir la actividad de las quimiocinas y/o el crecimiento de células cancerosas |
| EP3390378B1 (en) | 2015-12-17 | 2022-03-30 | AlonBio Ltd. | Small molecules against cancer |
| CN109789144B (zh) * | 2016-08-12 | 2022-04-15 | 马德拉医疗公司 | 蛋白激酶调节剂 |
| CA3043755A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
| EP3573619A4 (en) | 2017-01-27 | 2020-10-28 | SignalRX Pharmaceuticals, Inc. | THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| CN109748914B (zh) * | 2018-12-29 | 2021-05-25 | 上海珂臻医药科技有限公司 | 吡啶并嘧啶类化合物及其应用 |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| CN114096524B (zh) | 2019-05-15 | 2025-03-04 | 阿龙拜欧有限公司 | 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子 |
| AR121719A1 (es) | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| CN111533721B (zh) * | 2020-05-15 | 2022-04-26 | 浙江大学 | 苯并吡喃酮或喹啉酮类化合物及其应用 |
| US20240208964A1 (en) * | 2020-06-03 | 2024-06-27 | Pyridopyrimidines And Methods Of Their Use | Pyridopyrimidines and methods of their use |
| EP4284375A4 (en) * | 2021-02-01 | 2025-04-23 | Geode Therapeutics Inc. | PHOSPHOINOSITIDE 3-KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREFOR |
| KR20240004865A (ko) | 2021-05-03 | 2024-01-11 | 페트라 파마 코포레이션 | 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 |
| EP4347040A1 (en) | 2021-05-27 | 2024-04-10 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| CA3232906A1 (en) * | 2021-10-07 | 2023-04-13 | Alessandro Boezio | Pi3k-alpha inhibitors and methods of use thereof |
| WO2025136936A1 (en) * | 2023-12-19 | 2025-06-26 | Merck Sharp & Dohme Llc | Agonists of trem2 activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS604170A (ja) * | 1983-06-21 | 1985-01-10 | Nippon Shinyaku Co Ltd | キノロン誘導体 |
| US5703075A (en) * | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| HUT58310A (en) | 1988-12-21 | 1992-02-28 | Upjohn Co | Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them |
| EP0525123B1 (en) * | 1990-06-20 | 1997-09-17 | PHARMACIA & UPJOHN COMPANY | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
-
2001
- 2001-01-24 EP EP07009194A patent/EP1857443B1/en not_active Expired - Lifetime
- 2001-01-24 CN CNB018067522A patent/CN1263743C/zh not_active Expired - Fee Related
- 2001-01-24 ES ES01902568T patent/ES2286093T3/es not_active Expired - Lifetime
- 2001-01-24 AU AU2001230426A patent/AU2001230426C1/en not_active Ceased
- 2001-01-24 JP JP2001553268A patent/JP4820518B2/ja not_active Expired - Fee Related
- 2001-01-24 WO PCT/IB2001/000079 patent/WO2001053266A1/en not_active Ceased
- 2001-01-24 AU AU3042601A patent/AU3042601A/xx active Pending
- 2001-01-24 NZ NZ520300A patent/NZ520300A/en not_active IP Right Cessation
- 2001-01-24 DE DE60128655T patent/DE60128655T2/de not_active Expired - Lifetime
- 2001-01-24 DK DK01902568T patent/DK1257537T3/da active
- 2001-01-24 EP EP01902568A patent/EP1257537B1/en not_active Expired - Lifetime
- 2001-01-24 CA CA2398163A patent/CA2398163C/en not_active Expired - Fee Related
- 2001-01-24 CN CNA2006100847155A patent/CN1891699A/zh active Pending
- 2001-01-24 US US10/181,485 patent/US6977255B2/en not_active Expired - Fee Related
- 2001-01-24 AT AT01902568T patent/ATE363471T1/de active
- 2001-01-24 PT PT01902568T patent/PT1257537E/pt unknown
- 2001-01-24 AT AT07009194T patent/ATE551325T1/de active
- 2001-01-24 CN CNA200610084723XA patent/CN1891693A/zh active Pending
-
2004
- 2004-10-12 US US10/961,062 patent/US7405211B2/en not_active Expired - Fee Related
-
2007
- 2007-07-20 CY CY20071100971T patent/CY1108023T1/el unknown
-
2008
- 2008-01-24 US US12/019,061 patent/US7572791B2/en not_active Expired - Fee Related
- 2008-05-06 US US12/115,563 patent/US20080312233A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60128655D1 (de) | Durch einen morpholinrest substituierte therapeutische verbindungen | |
| WO2005082863A3 (en) | 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors | |
| JP2002525323A (ja) | 医薬活性化合物及びその使用方法 | |
| UA99308C2 (ru) | Аналог азацитидина и его применение | |
| ATE266007T1 (de) | Heterocyclische verbindungen als faktor xa inhibitoren | |
| LV12047A (lv) | Kondenseti pirimidina atvasinajumi un to lietosana par angiotenzina II antagonistiem | |
| BR0011295A (pt) | Aril e heteroaril pirazinonas policìclicas substituìdas úteis para inibição seletiva de cascata de coagulação | |
| JP2003512423A (ja) | 組織因子アンタゴニスト及びその使用方法 | |
| JP2005539049A (ja) | インテグリンと選択的に結合するピペリジニル化合物 | |
| NO20064295L (no) | Bruk av metylenamidderivater i kardiovaskulaere lidelser | |
| BR9914893A (pt) | Cromenona e derivados de cromanona como inibidores de integrina | |
| JP2009528293A5 (enExample) | ||
| DE69624829D1 (de) | Thienopyrimidinderivate als endothelin antagonisten | |
| ATE289299T1 (de) | Polyzyclisch aryl und heteroaryl substituierte 4- pyronen verwendbar als selektive hemmung von dem koagulationsprozess | |
| TR200103853T2 (tr) | Spiro bağlı trisiklik bileşikler. | |
| ATE491696T1 (de) | Neue 2,4-diaminothiazol-5-onderivate | |
| CN104610257B (zh) | 一类含酰胺结构的FXa抑制剂、制备方法及其用途 | |
| CN104557927B (zh) | 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途 | |
| CN104557929B (zh) | 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途 | |
| Singla et al. | Interplay between Hemostatic Pathways and Cancer Biology in Head and Neck Cancers | |
| CN104725374B (zh) | 一种含双酰胺基和腈基苯结构的FXa抑制剂及其用途 | |
| CN104557930B (zh) | 一种含二环酰胺结构凝血因子Xa抑制剂及其用途 | |
| Abdelfadiel | ASSESSING DRUG DEVELOPMENT PROPORTIES OF ANTITHROMBOTIC AND ANTI-CANCER AGENTS | |
| CN105085346B (zh) | 含胺基的l-薄荷醇类p2y12受体拮抗剂及其用途 | |
| WO2002049649A3 (de) | Pharmazeutische formulierung enthaltend thienopyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate (2) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1257537 Country of ref document: EP |